work areas
The Medicines Evaluation Board (MEB) evaluates and monitors the
efficacy, risks and quality of:
Human Medicinal
Products
The Medicines Evaluation Board is
responsible for authorising and monitoring safe and effective
medicinal products on the Dutch market and shares in responsibility
for authorising medicinal products throughout the European Union.
Before a medicinal product can be sold in the Netherlands, it has
to receive marketing authorisation from the MEB. The MEB evaluates
the medicinal product and decides on the conditions under which it
can be placed on the Dutch market. It also decides on the product's
legal status (whether it can be obtained without prescription or
whether it may only be dispensed on prescription).
If you would like more information about this area of activity
(human medicinal products), click on 'Topics on work
areas' on the menu to the right.
Veterinary Medicinal
Products
The Medicines Evaluation Board assesses
veterinary medicinal products (medicines for animals) as well as
human medicinal products. The MEB's Veterinary Medicinal Products
Unit is responsible for assessing and authorising veterinary
medicinal products for both the Dutch and European markets and for
monitoring veterinary medicinal products once they have been
granted marketing authorisation.
If you would like more information about this area of activity
(veterinary medicinal products), click on 'Topics on work
areas' on the menu to the right.
Novel foods
The Medicines
Evaluation Board assesses novel foods as well as medicinal
products. Before a novel food is placed on the market, it has to be
scientifically assessed to make sure that it is safe for consumers.
Novel foods are assessed by the MEB's Novel Foods Unit.
If you would like more information about this area of activity
(novel foods), click on 'Topics on work areas' on the
menu to the right.